Consistent with this notion, IDH mutations in gliomas have been shown to be highly associated with certain other mutations, most notably TP53 mutations or 1q/19q co-deletions, and studies on their timing suggest that they typically precede these mutations [9,10,11,12]. The gene discussed is IDH2; the disease is central nervous system cancer.